Advanced Therapeutic Intervention for GBA1-Associated Parkinson's Disease: Preclinical Evaluation of Efficacy and Safety of LY-N001

被引：0

|

作者：

Cai, Yingying ^{[1
]}

Yan, Guofang ^{[1
]}

Sheng, Xiaojing ^{[1
]}

Chen, Yixiong ^{[1
]}

Lin, Qing ^{[1
]}

机构：

[1] Lingyi Biotech Co Ltd, Dept Discovery, Shanghai, Peoples R China

来源：

MOLECULAR THERAPY | 2024年 / 32卷 / 04期

关键词：

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

1111

引用

收藏

页码：528 / 528

页数：1

相关论文

共 24 条

[21] A large phase III study to evaluate the safety and efficacy of sarizotan in the treatment of L-dopa-induced dyskinesia associated with Parkinson's disease: The Paddy-1 study
Rascol, O.
Damier, P.
Goetz, C. G.
Hicking, C.
Hock, K.
Muller, T.
Olanow, C. W.
Russ, H.
Paddy, S.
MOVEMENT DISORDERS, 2006, 21 : S492 - S493
[22] Phase 1/2 Open-label Dose Evaluation Study of AXO-Lenti-PD Gene Therapy for Parkinson's Disease: Efficacy, Safety, and Tolerability Data up to 24 Months
Corcoran, G.
Karunakara, A.
Dumayas, E.
Valencia, D.
De Boever, E.
Foltynie, T.
Barker, R. A.
Palfi, S.
HUMAN GENE THERAPY, 2021, 32 (19-20) : A107 - A107
[23] Long-Term Safety and Efficacy of Foscarbidopa/Foslevodopa in Patients with Advanced Parkinson's disease (PD): Results from an Ongoing Phase 3 Open-Label Extension with Up to 1 Year Follow-Up
Hauser, R.
Fung, V.
Kimber, T.
Klos, K.
Facheris, M.
Jeong, A.
Jia, J.
Spiegel, A.
Soileau, M.
MOVEMENT DISORDERS, 2024, 39 : S317 - S318
[24] Phase 1/2 Open-label Dose Evaluation Study of AXO-Lenti-PD Gene Therapy for Parkinson's Disease: Efficacy, Safety, and Tolerability Data from the Second Cohort at 6 Months
Corcoran, G.
Karunakara, A.
Vaughn, B.
Brand-Schieber, E.
Foltynie, T.
Barker, R.
Palfi, S.
MOVEMENT DISORDERS, 2021, 36 : S167 - S167